Omalizumab for severe allergic asthma: 7 years and open questions

Respiration. 2014;88(2):158-61. doi: 10.1159/000360771. Epub 2014 May 9.


Anti-IgE treatment for severe allergic asthma has been available for more than seven years now. This treatment has clear clinical benefits and a good safety record. However, important questions concerning long-term dosing and treatment duration remain unanswered. This paper discusses the available information concerning the long-term use of omalizumab.

Publication types

  • Review

MeSH terms

  • Anti-Allergic Agents / therapeutic use*
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Humans
  • Omalizumab


  • Anti-Allergic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Omalizumab